Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studies

Autores
Tesan, Fiorella Carla; Cerqueira Coutinho, Cristal; Salgueiro, María Jimena; Albernaz, Marta de Souza; Pinto, Suyenne Rocha; Reis, Sara Rhaissa Rezende Dos; Bernardes, Emerson Soares; Chiapetta, Diego; Zubillaga, Marcela Beatriz; Santos Oliveira, Ralph
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Bevacizumab is an FDA approved monoclonal antibody (anti VEGF) indicated in many cancers, mostly metastatic ones. D-α-tocopheryl polyethylene glycol succinate (TPGS) is the water-soluble form of vitamin E which usually forms micelles. This work aims to report preliminary results of the biodistribution of a TPGS based nano-micelle delivery system for bevacizumab in a gastric cancer xenograft model. Evaluation of the biodistribution of micelles/bevacizumab-99mTc was performed in Balb/c nude mice carrying MKN45 cell line xenograft. The nano-radiopharmaceutical (3.7 MBq/0.2 mL) was administered intraocularly and biodistribution was assesed 1 h post administration. The activity in each organ and blood was determined by a gamma counter. Mean size was 10 ± 1 nm for pure TPGS and 11 ± 1 nm for bevacizumab-TPGS respectively. Biodistribution showed that the highest uptake was found in both lungs and liver. Kidneys had also an important uptake. The tumor accumulated moderate to low radiolabeled nanomicelles, nevertheless tumor/blood ratio was very high. These preliminary results may help as a start point to continue evaluating the potential of radiolabeled bevacizumab-TPGS based nanomicelles to be used as a theranostic agent.
Fil: Tesan, Fiorella Carla. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentina
Fil: Cerqueira Coutinho, Cristal. Universidade Federal do Rio de Janeiro; Brasil
Fil: Salgueiro, María Jimena. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentina
Fil: Albernaz, Marta de Souza. Universidade Federal do Rio de Janeiro; Brasil
Fil: Pinto, Suyenne Rocha. Universidade Estadual da Zona Oeste; Brasil
Fil: Reis, Sara Rhaissa Rezende Dos. Universidade Estadual da Zona Oeste; Brasil
Fil: Bernardes, Emerson Soares. Instituto de Pesquisas Energéticas e Nucleares; Brasil
Fil: Chiapetta, Diego. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Zubillaga, Marcela Beatriz. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Santos Oliveira, Ralph. Universidade Estadual da Zona Oeste; Brasil
Materia
Bevacizumab
Biodistribution
Mkn45
Nanomicelles
Tpgs
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/40144
Acceder
id CONICETDig_5efce90011720db0ca3c621ef3adc14e
oai_identifier_str oai:ri.conicet.gov.ar:11336/40144
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studiesTesan, Fiorella CarlaCerqueira Coutinho, CristalSalgueiro, María JimenaAlbernaz, Marta de SouzaPinto, Suyenne RochaReis, Sara Rhaissa Rezende DosBernardes, Emerson SoaresChiapetta, DiegoZubillaga, Marcela BeatrizSantos Oliveira, RalphBevacizumabBiodistributionMkn45NanomicellesTpgshttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Bevacizumab is an FDA approved monoclonal antibody (anti VEGF) indicated in many cancers, mostly metastatic ones. D-α-tocopheryl polyethylene glycol succinate (TPGS) is the water-soluble form of vitamin E which usually forms micelles. This work aims to report preliminary results of the biodistribution of a TPGS based nano-micelle delivery system for bevacizumab in a gastric cancer xenograft model. Evaluation of the biodistribution of micelles/bevacizumab-99mTc was performed in Balb/c nude mice carrying MKN45 cell line xenograft. The nano-radiopharmaceutical (3.7 MBq/0.2 mL) was administered intraocularly and biodistribution was assesed 1 h post administration. The activity in each organ and blood was determined by a gamma counter. Mean size was 10 ± 1 nm for pure TPGS and 11 ± 1 nm for bevacizumab-TPGS respectively. Biodistribution showed that the highest uptake was found in both lungs and liver. Kidneys had also an important uptake. The tumor accumulated moderate to low radiolabeled nanomicelles, nevertheless tumor/blood ratio was very high. These preliminary results may help as a start point to continue evaluating the potential of radiolabeled bevacizumab-TPGS based nanomicelles to be used as a theranostic agent.Fil: Tesan, Fiorella Carla. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; ArgentinaFil: Cerqueira Coutinho, Cristal. Universidade Federal do Rio de Janeiro; BrasilFil: Salgueiro, María Jimena. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; ArgentinaFil: Albernaz, Marta de Souza. Universidade Federal do Rio de Janeiro; BrasilFil: Pinto, Suyenne Rocha. Universidade Estadual da Zona Oeste; BrasilFil: Reis, Sara Rhaissa Rezende Dos. Universidade Estadual da Zona Oeste; BrasilFil: Bernardes, Emerson Soares. Instituto de Pesquisas Energéticas e Nucleares; BrasilFil: Chiapetta, Diego. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Zubillaga, Marcela Beatriz. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Santos Oliveira, Ralph. Universidade Estadual da Zona Oeste; BrasilElsevier Science2016-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/40144Tesan, Fiorella Carla; Cerqueira Coutinho, Cristal; Salgueiro, María Jimena; Albernaz, Marta de Souza; Pinto, Suyenne Rocha; et al.; Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studies; Elsevier Science; Journal of Drug Delivery Science and Technology; 36; 12-2016; 95-981773-2247CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S1773224716301216info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jddst.2016.09.011info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:38:33Zoai:ri.conicet.gov.ar:11336/40144instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:38:33.493CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studies
title Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studies
spellingShingle Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studies
Tesan, Fiorella Carla
Bevacizumab
Biodistribution
Mkn45
Nanomicelles
Tpgs
title_short Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studies
title_full Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studies
title_fullStr Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studies
title_full_unstemmed Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studies
title_sort Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studies
dc.creator.none.fl_str_mv Tesan, Fiorella Carla
Cerqueira Coutinho, Cristal
Salgueiro, María Jimena
Albernaz, Marta de Souza
Pinto, Suyenne Rocha
Reis, Sara Rhaissa Rezende Dos
Bernardes, Emerson Soares
Chiapetta, Diego
Zubillaga, Marcela Beatriz
Santos Oliveira, Ralph
author Tesan, Fiorella Carla
author_facet Tesan, Fiorella Carla
Cerqueira Coutinho, Cristal
Salgueiro, María Jimena
Albernaz, Marta de Souza
Pinto, Suyenne Rocha
Reis, Sara Rhaissa Rezende Dos
Bernardes, Emerson Soares
Chiapetta, Diego
Zubillaga, Marcela Beatriz
Santos Oliveira, Ralph
author_role author
author2 Cerqueira Coutinho, Cristal
Salgueiro, María Jimena
Albernaz, Marta de Souza
Pinto, Suyenne Rocha
Reis, Sara Rhaissa Rezende Dos
Bernardes, Emerson Soares
Chiapetta, Diego
Zubillaga, Marcela Beatriz
Santos Oliveira, Ralph
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Bevacizumab
Biodistribution
Mkn45
Nanomicelles
Tpgs
topic Bevacizumab
Biodistribution
Mkn45
Nanomicelles
Tpgs
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Bevacizumab is an FDA approved monoclonal antibody (anti VEGF) indicated in many cancers, mostly metastatic ones. D-α-tocopheryl polyethylene glycol succinate (TPGS) is the water-soluble form of vitamin E which usually forms micelles. This work aims to report preliminary results of the biodistribution of a TPGS based nano-micelle delivery system for bevacizumab in a gastric cancer xenograft model. Evaluation of the biodistribution of micelles/bevacizumab-99mTc was performed in Balb/c nude mice carrying MKN45 cell line xenograft. The nano-radiopharmaceutical (3.7 MBq/0.2 mL) was administered intraocularly and biodistribution was assesed 1 h post administration. The activity in each organ and blood was determined by a gamma counter. Mean size was 10 ± 1 nm for pure TPGS and 11 ± 1 nm for bevacizumab-TPGS respectively. Biodistribution showed that the highest uptake was found in both lungs and liver. Kidneys had also an important uptake. The tumor accumulated moderate to low radiolabeled nanomicelles, nevertheless tumor/blood ratio was very high. These preliminary results may help as a start point to continue evaluating the potential of radiolabeled bevacizumab-TPGS based nanomicelles to be used as a theranostic agent.
Fil: Tesan, Fiorella Carla. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentina
Fil: Cerqueira Coutinho, Cristal. Universidade Federal do Rio de Janeiro; Brasil
Fil: Salgueiro, María Jimena. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentina
Fil: Albernaz, Marta de Souza. Universidade Federal do Rio de Janeiro; Brasil
Fil: Pinto, Suyenne Rocha. Universidade Estadual da Zona Oeste; Brasil
Fil: Reis, Sara Rhaissa Rezende Dos. Universidade Estadual da Zona Oeste; Brasil
Fil: Bernardes, Emerson Soares. Instituto de Pesquisas Energéticas e Nucleares; Brasil
Fil: Chiapetta, Diego. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Zubillaga, Marcela Beatriz. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Santos Oliveira, Ralph. Universidade Estadual da Zona Oeste; Brasil
description Bevacizumab is an FDA approved monoclonal antibody (anti VEGF) indicated in many cancers, mostly metastatic ones. D-α-tocopheryl polyethylene glycol succinate (TPGS) is the water-soluble form of vitamin E which usually forms micelles. This work aims to report preliminary results of the biodistribution of a TPGS based nano-micelle delivery system for bevacizumab in a gastric cancer xenograft model. Evaluation of the biodistribution of micelles/bevacizumab-99mTc was performed in Balb/c nude mice carrying MKN45 cell line xenograft. The nano-radiopharmaceutical (3.7 MBq/0.2 mL) was administered intraocularly and biodistribution was assesed 1 h post administration. The activity in each organ and blood was determined by a gamma counter. Mean size was 10 ± 1 nm for pure TPGS and 11 ± 1 nm for bevacizumab-TPGS respectively. Biodistribution showed that the highest uptake was found in both lungs and liver. Kidneys had also an important uptake. The tumor accumulated moderate to low radiolabeled nanomicelles, nevertheless tumor/blood ratio was very high. These preliminary results may help as a start point to continue evaluating the potential of radiolabeled bevacizumab-TPGS based nanomicelles to be used as a theranostic agent.
publishDate 2016
dc.date.none.fl_str_mv 2016-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/40144
Tesan, Fiorella Carla; Cerqueira Coutinho, Cristal; Salgueiro, María Jimena; Albernaz, Marta de Souza; Pinto, Suyenne Rocha; et al.; Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studies; Elsevier Science; Journal of Drug Delivery Science and Technology; 36; 12-2016; 95-98
1773-2247
CONICET Digital
CONICET
url http://hdl.handle.net/11336/40144
identifier_str_mv Tesan, Fiorella Carla; Cerqueira Coutinho, Cristal; Salgueiro, María Jimena; Albernaz, Marta de Souza; Pinto, Suyenne Rocha; et al.; Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studies; Elsevier Science; Journal of Drug Delivery Science and Technology; 36; 12-2016; 95-98
1773-2247
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S1773224716301216
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jddst.2016.09.011
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier Science
publisher.none.fl_str_mv Elsevier Science
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846082864991436800
score 13.22299

Publicaciones similares